CD274 and metastatic malignant neoplasm in the lymph nodes: Further investigation is required to determine whether, and in which settings, reassessment of PD-L1 status in metastatic lesions-including lymph node metastases-may provide additional clinically relevant information when initial testing does not meet established therapeutic cut-offs.